Bangor Savings Bank’s iShares Biotechnology ETF IBB Stock Holding History

Bangor Savings Bank’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Hold	1,099	–	–	0.02%	203
2026 Q1	$186K	Hold	1,099	–	–	0.01%	207
2025 Q4	$185K	Hold	1,099	–	–	0.01%	207
2025 Q3	$159K	Sell	1,099 -466	-30%	-$63.6K	0.01%	216
2025 Q2	$198K	Hold	1,565	–	–	0.02%	199
2025 Q1	$200K	Sell	1,565 -713	-31%	-$96.7K	0.02%	201
2024 Q4	$301K	Hold	2,278	–	–	0.03%	185
2024 Q3	$332K	Hold	2,278	–	–	0.03%	181
2024 Q2	$313K	Sell	2,278 -229	-9%	-$30.6K	0.03%	181
2024 Q1	$344K	Hold	2,507	–	–	0.04%	177
2023 Q4	$341K	Hold	2,507	–	–	0.04%	173
2023 Q3	$307K	Sell	2,507 -25	-1%	-$3.18K	0.04%	170
2023 Q2	$321K	Sell	2,532 -133	-5%	-$17.3K	0.04%	170
2023 Q1	$344K	Sell	2,665 -18	-0.7%	-$2.36K	0.04%	162
2022 Q4	$352K	Hold	2,683	–	–	0.04%	159
2022 Q3	$314K	Sell	2,683 -9	-0.3%	-$1.12K	0.04%	164
2022 Q2	$317K	Sell	2,692 -1	-0%	-$119	0.03%	170
2022 Q1	$351K	Sell	2,693 -183	-6%	-$23.8K	0.04%	150
2021 Q4	$439K	Sell	2,876 -152	-5%	-$23.5K	0.04%	165
2021 Q3	$490K	Sell	3,028 -38	-1%	-$6.39K	0.05%	154
2021 Q2	$502K	Sell	3,066 -9,639	-76%	-$1.48M	0.06%	149
2021 Q1	$1.91M	Buy	12,705 +395	+3%	+$62.7K	0.23%	59
2020 Q4	$1.86M	Buy	12,310 +254	+2%	+$36.3K	0.25%	52
2020 Q3	$1.63M	Sell	12,056 -8,218	-41%	-$1.11M	0.25%	56
2020 Q2	$2.77M	Buy	20,274 +278	+1%	+$35.4K	0.45%	30
2020 Q1	$2.15M	Sell	19,996 -1,181	-6%	-$136K	0.4%	31
2019 Q4	$2.55M	Buy	21,177 +8,153	+63%	+$910K	0.4%	33
2019 Q3	$1.3M	Buy	13,024 +40	+0.3%	+$4.19K	0.22%	71
2019 Q2	$1.42M	Buy	+12,984	New	+$1.38M	0.25%	59
2016 Q1	–	Sell	-20,892	Closed	-$2.36M	–	137
2015 Q4	$2.36M	Buy	20,892 +201	+1%	+$21.8K	0.59%	28
2015 Q3	$2.09M	Sell	20,691 -1,377	-6%	-$165K	0.53%	35
2015 Q2	$2.71M	Sell	22,068 -4,308	-16%	-$516K	0.65%	26
2015 Q1	$3.02M	Buy	26,376 +2,181	+9%	+$241K	0.73%	23
2014 Q4	$2.45M	Buy	24,195 +3,060	+14%	+$297K	0.62%	24
2014 Q3	$1.93M	Sell	21,135 -936	-4%	-$82.1K	0.52%	37
2014 Q2	$1.89M	Sell	22,071 -372	-2%	-$29.3K	0.5%	39
2014 Q1	$1.77M	Sell	22,443 -4,749	-17%	-$396K	0.53%	37
2013 Q4	$2.06M	Sell	27,192 -1,863	-6%	-$132K	0.57%	39
2013 Q3	$2.03M	Sell	29,055 -444	-2%	-$29.1K	0.62%	32
2013 Q2	$1.71M	Buy	+29,499	New	+$1.71M	0.55%	40

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Bangor Savings Bank's IBB Position: Q2 2026 in Review

Bangor Savings Bank held its iShares Biotechnology ETF (IBB) position steady in Q2 2026 at 1,099 shares worth $209K. The position accounts for 0.02% of the portfolio, ranked #203.

Bangor Savings Bank first reported a position in IBB in Q2 2013 and has held it in 40 quarters since. The position peaked at $3.02M in Q1 2015. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Bangor Savings Bank held 1,099 shares of iShares Biotechnology ETF worth $209K as of Q2 2026.
Bangor Savings Bank left its iShares Biotechnology ETF share count unchanged in Q2 2026.
iShares Biotechnology ETF made up 0.02% of Bangor Savings Bank's portfolio in Q2 2026, its #203 holding.
Bangor Savings Bank first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 40 quarters since.
Bangor Savings Bank's iShares Biotechnology ETF position peaked at $3.02M in Q1 2015.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Bangor Savings Bank's 13F filing for Q2 2026, filed 6 Jul 2026.